BCAX — Bicara Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2023658 ·
Last close
$9.60
Market Cap
$637.32M
52W High
$30.99
52W Low
$7.87
ADV30
1,816,025
Next earnings
2026-11-09
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -75,711,000 -71,249,000 460,642,000 82,021,000 51,231,000
Jun 2026 0 — -59,951,000 -55,436,000 512,243,000 96,599,000 43,475,000
Mar 2026 0 — -60,242,000 -56,211,000 553,599,000 323,462,000 39,641,000
Dec 2025 0 — -41,122,000 -37,386,000 430,994,000 96,685,000 29,542,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-161,729,000
Investing CF
$-128,044,000
Financing CF
$200,121,000
CapEx
$-1,021,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.47
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-541,862,000
Inventory
—
Receivables
—
ST Investments
$360,325,000
EBIT TTM
$-237,026,000
Pretax Income TTM
$-220,062,000
Interest Exp TTM
—
Analysts
12

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -155,604,000 -137,950,000 430,994,000 29,542,000 401,452,000 -106,834,000
Dec 2024 0 -82,389,000 -67,995,000 509,996,000 18,121,000 491,875,000 -74,751,000
Dec 2023 0 -39,889,000 -51,985,000 233,982,000 382,751,000 -148,769,000 -45,628,000
Dec 2022 0 -37,656,000 -37,845,000 6,703,000 105,506,000 -98,803,000 -32,076,000

TTM Snapshot

Revenues TTM
$16,834,000
NetIncome TTM
$-185,363,000
OpCashFlow TTM
—
Assets (Latest)
$512,243,000
Forward EPS
$-3.89

Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $9.38 · call volume: 3 · put volume: 386

Peers — same industry

TickerNameMarket CapLastDaily %
OLMA Olema Oncology, Inc. $632.52M $7.22 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —
GERN GERON CORP $644.24M $1.00 —
DSGN Design Therapeutics, Inc. $630.12M $9.84 —
ALMS ALUMIS INC. $628.33M $4.84 —

News headlines (Yahoo Finance, 1h cache)

Bicara Therapeutics (BCAX) Stock Gets Fair Value Trim As Analysts Split On Ficera
2026-11-13 01:13 · Yahoo
Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ...
2026-11-10 11:02 · Yahoo
Bicara (BCAX) Q3 2026 Earnings Call Transcript
2026-11-09 19:43 · Yahoo
Bicara Therapeutics Inc. Common Stock Q3 2026 Earnings Call Summary
2026-11-09 17:55 · Yahoo
What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call
2026-11-09 16:15 · Yahoo
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 12:30 · Yahoo
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 13:30 · Yahoo
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
2026-11-02 13:30 · Yahoo
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value
2026-10-10 10:09 · Yahoo
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
2026-08-18 15:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.